Gland Pharma Ltd (GLAND) — Board Meeting | 13 September 2026 (3 announcements)

Gland Pharma's board addressed fines from NSE and BSE totaling ₹70,000 each for a 34-day technical breach involving the appointment of 75+ year-old Independent Director William Keller, which occurred during the mandatory postal ballot period. The company resolved the matter by paying both fines promptly and reaffirmed its commitment to strict compliance with SEBI LODR regulations.

Gland Pharma announced on September 13, 2026 that its Board approved the grant of 5,90,249 stock options to 124 employees under the 2025 ESOP scheme, with 34% vesting each year over three years starting September 13, 2027, at exercise prices of INR 1,461.15 (50% of NSE closing price on September 11, 2026) and INR 1 per share.

Gland Pharma announced the board approved acquiring 100% of Gland Pharma USA Inc. for USD 5,01,208 in cash to streamline its corporate structure. The target, incorporated in March 2022, had negligible turnover in FY26 and operated in the US pharmaceutical distribution sector. The transaction is a related party acquisition exempt from shareholder approval, with completion targeted by October 31, 2026.